{
    "Trade/Device Name(s)": [
        "HemosIL ReadiPlasTin"
    ],
    "Submitter Information": "Instrumentation Laboratory Company",
    "510(k) Number": "K213426",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122584"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GJS",
        "GIS"
    ],
    "Summary Letter Date": "August 16, 2022",
    "Summary Letter Received Date": "October 21, 2021",
    "Submission Date": "October 20, 2021",
    "Regulation Number(s)": [
        "21 CFR 864.7750",
        "21 CFR 864.7340"
    ],
    "Regulation Name(s)": [
        "Prothrombin time test",
        "Fibrinogen determination system"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Prothrombin Time",
        "Fibrinogen"
    ],
    "Specimen Type(s)": [
        "Human citrated plasma",
        "3.2% and 3.8% citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL TOP Family",
        "ACL TOP Family 50 Series"
    ],
    "Method(s)/Technology(ies)": [
        "Recombinant human tissue factor-based thromboplastin reagent",
        "PT-based quantitative determination"
    ],
    "Methodologies": [
        "Clotting-based measurement",
        "Absorbance or light scatter quantitation"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Diluent"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL ReadiPlasTin reagent for quantitative determination of Prothrombin Time and Fibrinogen on ACL TOP analyzers",
    "Indications for Use Summary": "In vitro diagnostic thromboplastin reagent for quantitative determination of Prothrombin Time and Fibrinogen in human citrated plasma, for evaluation of the extrinsic coagulation pathway and monitoring of Oral Vitamin K Antagonist Therapy, used on ACL TOP Family and ACL TOP Family 50 Series analyzers",
    "fda_folder": "Hematology"
}